Srinivas Akkaraju

Director Srinivas Akkaraju buys 244,300 KLRS shares at $4.83 ($1.2M); stock down 58.6% from 52-week high, -22.3% in 30 days.

Srinivas Akkaraju, a Director at unprofitable Kalaris Therapeutics (full-year net income: $-10,856,000.00), purchased 244,300 shares at $4.83 on 2026-05-20, bringing his holding to 19,408 shares post-transaction. The purchase represents a notable dollar commitment ($1,179,969.00) into a stock trading at $4.92 currently, down 58.6% from its 52-week high of $11.88 and off 50.8% over the past 90 days. His cross-ticker track record shows strong timing (20 prior buys averaging +197.1% 90-day returns with a 95.00% win rate), yet his single prior buy at KLRS (2025-12-18) produced a -27.7% 90-day return, indicating this ticker has not aligned with his typical execution pattern. The company's unprofitable status and continued downward price momentum provide limited fundamental support for the accumulation.

Director Akkaraju Srinivas bought 479,847 shares of KLRS at $10.42 ($5.0M), raising holdings by 32.0% as stock trades 28.0% below 52-week high.

Akkaraju Srinivas, a Director, deployed $5,000,005.74 to purchase 479,847 shares at $10.42, increasing his stake from 1,500,000 shares to 1,979,847 shares. This represents a 32.0% increase in his holdings. The purchase was made when the stock trades at $8.26, which is 28.0% below its 52-week high of $11.47 and 15.2% down over the past 30 days, suggesting the insider acquired shares following recent weakness. Notably, Srinivas's cross-ticker track record shows 20 prior open-market buys with an average 90-day return of +129.8% and a 100.00% win rate, though the company itself is unprofitable with net income of $-11,894,000.00 over its most recent full fiscal year. The large dollar commitment and aggressive holding expansion by an insider with a strong historical track record at capital deployment warrant investor attention, particularly given the depressed relative price at which the purchase occurred.

Director Akkaraju Srinivas buys 588,235 shares of ALMS at $17.00 ($10.0M); stock now at $22.11, +92.4% in 30 days. Cluster pattern: 3 other insiders also bought within 14 days.

Director Akkaraju Srinivas purchased 588,235 shares at $17.00 for $9,999,995.00 on 2026-01-09, increasing his holdings by 46.5% to 1,853,488 shares. The stock has appreciated sharply to $22.11 (currently at 52-week high), with a +92.4% gain in 30 days and +355.9% gain over 90 days. This buy occurs as part of a cluster pattern—3 other insiders purchased within the preceding 14 days—signaling coordinated accumulation activity. However, context is critical: the company generated only $2.1M in revenue and reported a net loss of $-110.8M in its most recent quarter, with full-year results also unprofitable. At this ticker, Srinivas's 5 prior buys show mixed near-term outcomes (ranging from -16.5% to +15.6% at 30 days), with no measurable 90-day results yet, and his cross-ticker track record (20 prior buys) shows a 100% 90-day win rate at +8.6% average—but that cross-ticker record does not necessarily predict performance in a company with severe profitability challenges.

Director Akkaraju Srinivas buys 29,599 shares (3 transactions on 2025-10-07) for $1,181,633.67 at SRRK, blended avg $39.92; post-trade holdings 6,367,614 shares (+0.5%)

Akkaraju Srinivas, a director at Scholar Rock Holding Corp, executed 3 separate purchases totaling 29,599 shares for $1,181,633.67 on 2025-10-07, at prices ranging from $39.31 to $40.97. The blended average transaction price of $39.92 compares favorably to the current price of $44.32, and the stock is +18.5% over 30 days and +38.7% over 90 days. However, his prior trades at SRRK tell a cautionary story: 5 recent buys (all within the prior 4 days) have returned -29.2%, -26.1%, -27.6%, -20.8%, and -19.4% at the 30-day mark, with only the most recent outcomes still unmeasurable at 90 days. His cross-ticker track record shows an average 30-day return of -3.2% across 20 prior buys, suggesting a pattern of purchases that have not delivered near-term gains. While the company showed strong revenue growth of +76.4% annually, it remains unprofitable with net income of $-102.2M in the latest full fiscal year, leaving fundamentals unresolved despite the recent stock momentum.

Director AKKARAJU SRINIVAS bought 186,377 shares across 3 transactions totaling $1,833,760.23, raising stake 17.3%

AKKARAJU SRINIVAS executed three separate purchases totaling 186,377 shares for $1,833,760.23 on 2025-12-05, with a blended average price of $9.84 per share. The current price of $11.43 sits at the 52-week high, and the stock has surged +142.2% in the last 30 days and +165.8% over 90 days; his purchases occurred during this explosive rally. His cross-ticker track record shows an average 30-day return of -25.0% on 20 prior buys, and his five recent same-ticker purchases at ALMS (2025-11-28 through 2025-12-04) have not yet reached measurable return windows. The company remains deeply unprofitable with $-110,752,000.00 net income (latest fiscal year) on only $2,066,000.00 quarterly revenue. This accumulation substantially increases his holdings from 1,078,876 to 1,265,253 shares, but the combination of poor historical buy-timing and severe fundamental distress warrants scrutiny of the transaction's underlying rationale.

Director Srinivas buys 262,027 shares in 3 tranches (Dec 2-4) at $7.79 avg; stock now $8.30, co unprofitable.

AKKARAJU SRINIVAS (Director) executed 3 separate purchases totaling 262,027 shares for $2,039,900.86 between 2025-12-02 and 2025-12-04, at prices ranging from $7.55 to $8.18 (blended average $7.79). His shareholding increased 32.1% from 816,849 to 1,078,876 shares. The purchases occur during a period of sharp upward price momentum: the stock is 30-day +82.4% and 90-day +84.0%, though it remains 17.6% below the 52-week high of $10.07. The fundamental backdrop is concerning: the company reported quarterly revenue of $2,066,000.00 and a net loss of $-110,752,000.00, with unprofitability over its most recent full fiscal year. A cluster pattern is present—3 other insiders also bought within the past 14 days. Srinivas's cross-ticker track record shows 20 prior buys with a 90-day win rate of 33.33% and average 90-day return of +10.9%, but his same-ticker history at ALMS consists of 5 recent buys (Nov 19 through Dec 1) with outcomes not yet measurable.

Director AKKARAJU SRINIVAS buys 173,589 shares in 3 tranches (173.6K) for $1,310,676.96 across 6 days at ALMS

AKKARAJU SRINIVAS purchased 173,589 shares in three separate transactions between 2025-11-26 and 2025-12-01, increasing his holdings by 27.0% to 816,849 shares total. The purchases occurred at prices of $7.64, $7.64, and $7.46, with a blended average of $7.55, during a period when the stock has appreciated 54.7% over 30 days and 56.4% over 90 days despite trading 27.0% below its 52-week high of $10.07. This buying activity coincides with a cluster pattern where 3 other insiders also purchased within the past 14 days. However, Alumis Inc. reported a net loss of $110,752,000.00 in its most recent full fiscal year and continues to operate unprofitably, with quarterly revenue of $2,066,000.00. The director's cross-ticker track record shows an average 90-day return of -6.3% on 19 prior buys with a 25.00% win rate, raising questions about the predictive value of this accumulation activity.

Director Akkaraju Srinivas bought 125,743 shares of ALMS at $7.20 on 2025-11-20 ($905.3K), raising stake 24.3%; stock down 29.5% from 52-week high despite 61.9% 30-day rally.

Srinivas purchased 125,743 shares at $7.20, increasing his stake from 517,517 to 643,260 shares. The transaction comes during volatile price action—while the stock has gained 61.9% over 30 days and 52.7% over 90 days, it remains 29.5% below its 52-week high and only marginally above the quarterly revenue run-rate. Importantly, his prior transaction at ALMS on 2025-05-05 produced a 90-day return of -21.6%, and a cluster of 3 other insiders also bought within the past 14 days. Fundamentally, the company is deeply unprofitable with net income of $-110.8M against quarterly revenue of $2.1M, raising concerns about whether this purchase reflects conviction or reflects an effort to steady a deteriorating financial position.

Director Srinivas buys 241,338 shares across 3 days (avg $6.34) for $1.5M; holdings up 87.4%

Akkaraju Srinivas, a Director, executed 3 separate purchases totaling 241,338 shares for $1,529,865.06 between November 17–19, 2025, increasing holdings from 276,179 to 517,517 shares. The company reported revenue of $2.1M and a net loss of $-110.8M in its latest quarter, indicating significant unprofitability. Srinivas's prior trades at ALMS show 0 of 3 prior buys were well-timed at the 90-day mark, with outcomes ranging from -35.3% to -9.0% over 90 days, whereas this filing coincides with a cluster buy pattern (3 other insiders also bought within 14 days). The stock has risen 38.0% over 30 days and 42.8% over 90 days but remains 36.5% below its 52-week high of $10.35.

Director Srinivas bought 276.2K ALMS shares at $5.25 ($1.4M); 0 of 3 prior buys well-timed at 90d, stock at -50.8% from high, co. posting -$110.8M net loss.

Director Akkaraju Srinivas purchased 276,179 shares of ALUMIS at $5.25, establishing an initial position, while the company reports a quarterly revenue of $2,066,000.00 paired with a net loss of -$110,752,000.00. His prior three purchases at ALMS all showed negative 90-day returns (ranging from -9.0% to -35.3%), with none well-timed by that mark. His cross-ticker buy track record shows an average 90-day return of +26.0% across 17 prior buys, yet his timing at this specific ticker has been consistently unfavorable. The stock trades -50.8% from its 52-week high of $11.35, and a cluster of three other insiders also bought within the past 14 days. This combination of persistent unprofitability, prior timing misses at this ticker, and the multi-insider purchase pattern suggests the market context warrants attention, though the director's historical execution at ALMS provides limited confidence in reversal outcomes.